The latest market report published by Credence Research, Inc. “Diabetic Macular Edema Treatment Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global diabetic macular edema treatment market was valued at US$ 3,094.55 Mn in 2016, and is expected to reach US$ 4,096.29 Mn by 2025 expanding at a CAGR of 3.1 % from 2017 to 2025.
[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]
The exact etiology of diabetic macular edema is not clear, but research findings in clinical trials indicate that it is a neurovascular disorder of the macula region found in the retina. Altered glial cells, death of endothelial cells and loss of pericytes have improved vasopermiability. The other factors studied that cause the disease are the upregulation of VEGF factors and the activation of AGE receptors. The treatment regimen for diabetic macular edema has modified from 1985 as laser photocoagulation therapy to post-2005 as intravitreal injections and anti-VEGF implants. According to studies cited in the 2015 American Academy of Ophthalmology study, some 21 million people worldwide are suffering from diabetic macular edema.
Photocoagulation laser therapy is used for the treatment of patients with focal diabetic macular edema, preferably with a yellow 577 nm micropulse laser pattern. Anti-VEGF medications are developed as intravitreal implants and intravitreal injections for the treatment of patients with diffuse diabetic macular edema.
North America is rising more in the market for diabetic macular edema therapy due to an increasing number of patients with type 2 diabetes. The number of patients suffering from diabetic retinopathy will rise from 5.5 million in 2005 to 16 million by 2050. Presence of top-tier photocoagulation laser manufacturers can result in accurate diagnosis of disease progression of diabetic macular edema and effective treatment regimen. The Asian Pacific market has a competitive market due to the presence of major domestic players manufacturing photocoagulation lasers. Rising prevalence of diabetic retinopathy, with a rise of 23 per cent over the last decade, has increased Asia Pacific’s market growth.
The diabetic macular edema treatment market includes major players such as LUMENIS, Novartis AG, Allergan, Inc., IRIDEX Corporation, Alimera Sciences, Bausch and Lomb Incorporated, Carl Zeiss Meditec AG, Ellex, Genetech, Inc., Quantel-Medical and Regeneron Pharmaceuticals, Inc.
Key Market Movements:
Rising prevalence of diabetic retinopathy with disease prognosis for diabetic macular edema
Promising product pipeline with improved drug efficacy and safety to push the growth of diabetic macular edema treatment market
Increasing funding in the research and development segment of ophthalmic care primarily focusing on intravitreal implants